News from Nanoscope
Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
Six-month data from Phase 2 STARLIGHT trial expected in H1 2023
“Stargardt disease is a blinding condition affecting adults and children alike. It is the most common macular dystrophy and has no established treatment,” said Byron Lam, MD, Robert Z. & Nancy J. Greene Chair and Professor of Ophthalmology at the University of Miami and principal investigator in the Phase 2 STARLIGHT trial. “MCO-010 has the potential to improve visual function in RP and Stargardt patients, and we look forward to seeing the data from this study.”
Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.